**PROMPT:**

Assessment & Recommendation:  Follow-up in 3 months

**RESPONSE:**

 , then every 3 months thereafter until resolution or discontinuance of the medication.  Treatment:  Avoidance during active illness, for at least 7 days.  Outcome:   Medication was taken at a reduced dose, in the hope that the infection would recur  Nausea, vomiting, dyspepsia, headache  Patient 1 ******** N/A  1.0 Initial Assessment:  Erythema multiforme of the mouth, tongue and/or throat, with nausea and vomiting.  Clinical Features:   Nausea, vomiting and dyspepsia with or without diaphoresis.  Note:  There was no fever.  2.0 Hospitalisation:   On post-operative day 2, there was further improvement, and on day 5 the patient was able to eat normally.  Interventions:  The patient was provided with a meal containing the same antimicrobial agents as those used during the initial assessment to control the infection.  Outcome:   A reduction in the number of days needed to pass from symptoms of dyspepsia and nausea to at least one day without these and a decrease in their frequency.  3.0 Outcome (follow-up) for outcome 10:  Nausea, vomiting, dyspepsia and/or diapause.  Nausea, vomiting, dyspepsia and/or diapause Patient 2 ******** ****** N/A Initial Assessment:  Erythema multiforme of the mouth, tongue and/or throat, with nausea and vomiting.  Clinical Features: There was no fever.  3.0 Hospitalisation: The patient was well in the following hours, and the infection was controlled with a single course of cefixime.  Interventions:  It was decided to discontinue the cefixime, and given a single dose of rifampicin as a replacement therapy.  Outcome:  There was no relapse.  ** Patients 2 and 3 are identical, except Patient 2 had an ileocolic erythema multiforme.  4.0 Outcome (follow-up) for outcome 9:  Nausea, vomiting, dyspepsia and/or diaphoresis, on duloxetine.  Nausea, vomiting and dyspepsia and